Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Cancer Res. 2017 May 16;77(13):3502–3512. doi: 10.1158/0008-5472.CAN-16-2745

Figure 3. Oncogenic validation of NTRK2 fusions.

Figure 3

(A) Schematic illustration of NTRK2 fusion genes. (B) Ba/F3 cell survival assay for NTRK2 fusions (mean luminescence, error bars denote standard deviation, N=3) compared to positive control, ETV6-NTRK3, GFP = negative control. (C) MCF-10A anchorage-independent colony formation assays for NTRK2 fusions (mean colony count from 10 random areas, error bars denote standard deviation, N=3). GFP = negative control. (D) Dose-dependent survival assays of Ba/F3 cells expressing AFAP1-NTRK2 and SQSTM1-NTRK2 treated with entrectinib for 72 hours (mean percentage of cell survival, error bars denote standard deviation, N=4). All p-values calculated by t-test; ns, not significant; *, p<0.05; ****, p<0.0001.